Compared to early breast cancer, HR+/HER2− metastatic breast cancer shows an increasing trend in SBS2 and SBS13 signatures.
← all excerpts
APOBEC in breast cancer: a dual player in tumor evolution and therapeutic response.
1
—
—
Compared to early breast cancer, HR+/HER2− metastatic breast cancer shows an increasing trend in SBS2 and SBS13 signatures.